Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas

• Published in: Cytokine (Philadelphia, Pa.) Vol. 73; no. 2; pp. 219 - 224
• Main Authors: Sebestyén, Anna, Márk, Ágnes, Hajdu, Melinda, Nagy, Noémi, Molnár, Anna, Végső, Gyula, Barna, Gábor, Kopper, László
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2015
• Subjects: Animals; Apoptosis; Apoptosis - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Humans; Lymphoma; Lymphoma, Non-Hodgkin - metabolism; Lymphoma, Non-Hodgkin - pathology; Mice, SCID; mTOR; Protein-Serine-Threonine Kinases - metabolism; Rapamycin; Receptors, Transforming Growth Factor beta - metabolism; Signal Transduction - drug effects; Sirolimus - pharmacology; Smad4 Protein - metabolism; TGF-β; Transforming Growth Factor beta1 - pharmacology; Xenograft Model Antitumor Assays; mTOR; TGF-β; Rapamycin; Lymphoma; Apoptosis

•PI3K/mTOR activity contributes to resistance of TGF-β1 in high grade lymphoma cells.•Rapamycin enhances the apoptotic effects of TGF-β1 in B lymphoma cells.•Smad4-independent, PP2A-dependent effect of rapamycin+TGF-β1 in certain cells.•mTOR inhibition may restore sensitivity to endogenous regulator...